Log in to save to my catalogue

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute...

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_03934196v1

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

About this item

Full title

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2022-12, Vol.400 (10367), p.1938-1952

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.
In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guid...

Alternative Titles

Full title

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_inserm_03934196v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_03934196v1

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(22)02076-1

How to access this item